CCND2 rearrangements are the most frequent genetic events in cyclin D1 - mantle cell lymphoma

Blood

Volumn 121, Issue 8, 2013, Pages 1394-1402

  Salaverria, Itziar ^a,b   Royo, Cristina ^a   Carvajal Cuenca, Alejandra ^a   Clot, Guillem ^a   Navarro, Alba ^a   Valera, Alejandra ^a   Song, Joo Y ^c   Woroniecka, Renata ^d   Rymkiewicz, Grzegorz ^d   Klapper, Wolfram ^e   Hartmann, Elena M ^f   Sujobert, Pierre ^g   Wlodarska, Iwona ^h   Ferry, Judith A ⁱ   Gaulard, Philippe ^g   Ott, German ^j   Rosenwald, Andreas ^f   Lopez Guillermo, Armando ^k   Quintanilla Martinez, Leticia ^l   Harris, Nancy L ⁱ   Jaffe, Elaine S ^c   Siebert, Reiner ^b   Campo, Elias ^a   Bea, Sílvia ^a   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e UNIVERSITY OF KIEL   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g HENRI MONDOR HOSPITAL   (France)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j ROBERT BOSCH HOSPITAL   (Germany)

^k HOSPITAL CLÍNIC   (Spain)

^l UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; GEMCITABINE; IMMUNOGLOBULIN LIGHT CHAIN; KI 67 ANTIGEN; OXALIPLATIN; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR SOX11; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; CLINICAL FEATURE; COPY NUMBER VARIATION; DISEASE COURSE; FEMALE; GENE DELETION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE MUTATION; GENE TRANSLOCATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LYMPHADENOPATHY; MALE; MANTLE CELL LYMPHOMA; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 84874407720     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-08-452284     Document Type: Article

References (33)

1. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7(10):750-762. (Pubitemid 47463673)
2. Royo C, Salaverria I, Hartmann EM, et al. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol. 2011;21(5):322-334.
3. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinico-pathologic study based on gene expression profiling. Blood. 2005;106(13):4315-4321. (Pubitemid 41775942)
4. Gesk S, Klapper W, Martin-Subero JI, et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood. 2006;108(3):1109-1110. (Pubitemid 44154656)
5. Shiller SM, Zieske A, Holmes H, III, et al. CD5-positive, cyclinD1-negative mantle cell lymphoma with a translocation involving the CCND2 gene and the IGL locus. Cancer Genet. 2011;204(3):162-164.
6. Herens C, Lambert F, Quintanilla-Martinez L et al. Cyclin D1-negative mantle cell lymphoma with cryptic t (12;14) (p13;q32) and cyclin D2 over-expression. Blood. 2008;111(3):1745-1746. (Pubitemid 351213474)
7. Quintanilla-Martinez L, Slotta-Huspenina J, Koch I, et al. Differential diagnosis of cyclin D2 + mantle cell lymphoma based on fluorescence in situ hybridization and quantitative real-time-PCR. Haematologica. 2009;94(11):1595-1598.
8. Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t (11;14)-negative mantle cell lymphomas. Blood. 2008;111(12):5683-5690.
9. Sonoki T, Harder L, Horsman DE, et al. Cyclin D3 is a target gene of t (6;14) (p21.1;q32.3) of mature B-cell malignancies. Blood. 2001;98(9):2837-2844.
10. Yatabe Y, Suzuki R, Tobinai K, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000;95(7):2253-2261. (Pubitemid 30167722)
11. Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lym-phoma. Blood. 2011;118(18):4808-4816.
12. Mozos A, Royo C, Hartmann E, et al. SOX11 expression is highly specific for mantle cell lym-phoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94(11):1555-1562.
13. Metcalf RA, Zhao S, Anderson MW, et al. Characterization of D-cyclin proteins in hematolymphoid neoplasms: lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes. Mod Pathol. 2010;23(3):420-433.
14. Zeng W, Fu K, Quintanilla-Fend L, et al. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression. Am J Surg Pathol. 2012;36(2):214-219.
15. Fernandez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408-1418.
16. Hsiao SC, Cortada IR, Colomo L, et al. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lym-phoma. Histopathology. 2012;61(4):685-693.
17. Ek S, Dictor M, Jerkeman M, Jirstrom K, Borrebaeck CA. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. 2008;111(2):800-805.
18. Dictor M, Ek S, Sundberg M, et al. Strong lym-phoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haemato-logica. 2009;94(11):1563-1568.
19. Carvajal-Cuenca A, Sua LF, Silva NM, et al. In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica. 2012;97(2):270-278.
20. Zettl A, Strobel P, Wagner K, et al. Recurrent genetic aberrations in thymoma and thymic carcinoma. Am J Pathol. 2000;157(1):257-266. (Pubitemid 30642585)
21. Lepretre F, Villenet C, Quief S, et al. Waved aCGH: to smooth or not to smooth. Nucleic Acids Res. 2010;38(7):e94.
22. Salaverria I, Zettl A, Bea S, et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol. 2007;25(10):1216-1222. (Pubitemid 46640567)
23. Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood. 2010;116(6):953-961.
24. Bea S, Salaverria I, Armengol L, et al. Uniparen-tal disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood. 2009;113(13):3059- 3069.
25. Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia. 2012;26(8):1895-1898.
26. Bea S, Ribas M, Hernandez JM, et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood. 1999;93(12):4365-4374. (Pubitemid 29279280)
27. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
28. Puente XS, Pinyol M, Quesada V, et al. Wholegenome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
29. Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490(7418):116-120.
30. Novara F, Beri S, Bernardo ME, et al. Different molecular mechanisms causing 9p21 deletions in acute lymphoblastic leukemia of childhood. Hum Genet. 2009;126(4):511-520.
31. Tagawa H, Seto M. AmicroRNA cluster as a target of genomic amplification in malignant lym-phoma. Leukemia. 2005;19(11):2013-2016. (Pubitemid 41554018)
32. Navarro A, Bea S, Fernandez V, et al. MicroRNA expression, chromosomal alterations, and immu-noglobulin variable heavy chain hypermutations in Mantle cell lymphomas. Cancer Res. 2009;69(17):7071-7078.
33. Olive V, Jiang I, He L. mir-17-92, a cluster of miR-NAs in the midst of the cancer network. Int J Biochem Cell Biol. 2010;42(8):1348-1354.